Floatz logo

hc-7366

Phase 1b

M.D. Anderson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Phase 1b cohort.

Asset / SponsorPhaseRating
Ipilimumab
M.D. Anderson Cancer Center
Phase 1CC
Nivolumab
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

hc-7366 is also rated in:

SHARKDormant
CC
Indicative ·
43 / 100
View asset →
HC-7366Dormant
CC
Indicative ·
43 / 100
View asset →
colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →